These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 15834715)

  • 21. NS0 cell damage by high gas velocity sparging in protein-free and cholesterol-free cultures.
    Zhu Y; Cuenca JV; Zhou W; Varma A
    Biotechnol Bioeng; 2008 Nov; 101(4):751-60. PubMed ID: 18814288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in the glycosylation profile of a monoclonal antibody produced by hybridomas cultured in serum-supplemented, serum-free or chemically defined media.
    Serrato JA; Hernández V; Estrada-Mondaca S; Palomares LA; Ramírez OT
    Biotechnol Appl Biochem; 2007 Jun; 47(Pt 2):113-24. PubMed ID: 17250495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety issues of animal products used in serum-free media.
    Merten OW
    Dev Biol Stand; 1999; 99():167-80. PubMed ID: 10404888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fed-batch bioreactor process scale-up from 3-L to 2,500-L scale for monoclonal antibody production from cell culture.
    Yang JD; Lu C; Stasny B; Henley J; Guinto W; Gonzalez C; Gleason J; Fung M; Collopy B; Benjamino M; Gangi J; Hanson M; Ille E
    Biotechnol Bioeng; 2007 Sep; 98(1):141-54. PubMed ID: 17657776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A sensitivity analysis of the fed-batch animal-cell bioreactor with respect to some control parameters.
    Lavric V; Ofiţeru ID; Woinaroschy A
    Biotechnol Appl Biochem; 2005 Feb; 41(Pt 1):29-35. PubMed ID: 15270673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The recovery of highly purified biopharmaceuticals from perfusion cell culture bioreactors.
    Prior CP; Doyle KR; Duffy SA; Hope JA; Moellering BJ; Prior GM; Scott RW; Tolbert WR
    J Parenter Sci Technol; 1989; 43(1):15-23. PubMed ID: 2926601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aqueous two-phase systems: A viable platform in the manufacturing of biopharmaceuticals.
    Rosa PA; Ferreira IF; Azevedo AM; Aires-Barros MR
    J Chromatogr A; 2010 Apr; 1217(16):2296-305. PubMed ID: 19962707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of intracellular nucleotide and nucleotide sugar contents on recombinant interferon-gamma glycosylation during batch and fed-batch cultures of CHO cells.
    Kochanowski N; Blanchard F; Cacan R; Chirat F; Guedon E; Marc A; Goergen JL
    Biotechnol Bioeng; 2008 Jul; 100(4):721-33. PubMed ID: 18496872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in large-scale production of monoclonal antibodies and related proteins.
    Shukla AA; Thömmes J
    Trends Biotechnol; 2010 May; 28(5):253-61. PubMed ID: 20304511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achievement of high cell density and high antibody productivity by a controlled-fed perfusion bioreactor process.
    Yang JD; Angelillo Y; Chaudhry M; Goldenberg C; Goldenberg DM
    Biotechnol Bioeng; 2000 Jul; 69(1):74-82. PubMed ID: 10820333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of selected control strategies for fed-batch cultures of a hybridoma cell line.
    Pörtner R; Schwabe JO; Frahm B
    Biotechnol Appl Biochem; 2004 Aug; 40(Pt 1):47-55. PubMed ID: 15270707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mcl-1 overexpression leads to higher viabilities and increased production of humanized monoclonal antibody in Chinese hamster ovary cells.
    Majors BS; Betenbaugh MJ; Pederson NE; Chiang GG
    Biotechnol Prog; 2009; 25(4):1161-8. PubMed ID: 19551877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of p21cip1 in adaptation of CHO cells to suspension and protein-free culture.
    Astley K; Naciri M; Racher A; Al-Rubeai M
    J Biotechnol; 2007 Jun; 130(3):282-90. PubMed ID: 17544163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioreactor technology: a novel industrial tool for high-tech production of bioactive molecules and biopharmaceuticals from plant roots.
    Sivakumar G
    Biotechnol J; 2006 Dec; 1(12):1419-27. PubMed ID: 17136730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Industrial processes with animal cells.
    Kretzmer G
    Appl Microbiol Biotechnol; 2002 Jul; 59(2-3):135-42. PubMed ID: 12111138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upstream processes in antibody production: evaluation of critical parameters.
    Jain E; Kumar A
    Biotechnol Adv; 2008; 26(1):46-72. PubMed ID: 17920803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of culture conditions on the N-glycosylation of a monoclonal antibody specific for recombinant hepatitis B surface antigen.
    Cabrera G; Cremata JA; Valdés R; García R; González Y; Montesino R; Gómez H; González M
    Biotechnol Appl Biochem; 2005 Feb; 41(Pt 1):67-76. PubMed ID: 15049731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The status of membrane bioreactor technology.
    Judd S
    Trends Biotechnol; 2008 Feb; 26(2):109-16. PubMed ID: 18191260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC.
    Kanda Y; Yamane-Ohnuki N; Sakai N; Yamano K; Nakano R; Inoue M; Misaka H; Iida S; Wakitani M; Konno Y; Yano K; Shitara K; Hosoi S; Satoh M
    Biotechnol Bioeng; 2006 Jul; 94(4):680-8. PubMed ID: 16609957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inducible product gene expression technology tailored to bioprocess engineering.
    Weber W; Fussenegger M
    Curr Opin Biotechnol; 2007 Oct; 18(5):399-410. PubMed ID: 17933507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.